Pharmaceutical

Sanofi backs development of Graviton’s treatments for serious diseases

Graviton Bioscience has secured a strategic investment from Sanofi to propel the development of ROCK2 inhibitors for serious diseases.

Feb 2, 2024 - 18:00
Sanofi backs development of Graviton’s treatments for serious diseases
Graviton Bioscience has secured a strategic investment from Sanofi to propel the development of ROCK2 inhibitors for serious diseases.
Read the original article

Tags:

Previous Article

Biosyngen’s liver cancer therapy receives fast track designation

Next Article

Tyra Biosciences’ TYRA-300 gains FDA rare paediatric disease status

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

A looming penicillin shortage threatens pregnant adults with syphilis and their newborns

A looming penicillin shortage threatens pregnant adults...

Jun 22, 2023

AstraZeneca’s STRIDE shows improved outcomes for liver cancer patients

AstraZeneca’s STRIDE shows improved outcomes for liver ...

Jun 29, 2023

Opinion: The CDC’s new, relaxed Covid isolation guidance makes perfect sense

Opinion: The CDC’s new, relaxed Covid isolation guidanc...

Mar 6, 2024